摘要
目的观察血必净对脓毒症(Sepsis)患者病情严重程度、体内炎性介质及发病率和病死率的影响,探讨对SEPSIS的免疫调节作用机制。方法60例脓毒症患者随机分为治疗组(30例)和对照组(30例),对照组给予常规综合治疗,治疗组加用血必净注射液治疗。观察患者的临床表现及预后,监测血浆前降钙素(PCT)、肿瘤坏死因子-α(TNF-a)、白细胞介素IL-1β、IL-6等指标。结果与对照组比较,血必净治疗组患者血浆前降钙素水平显著降低,并下调促炎介质TNF-α、IL-1β、IL-6(P<0.05)。同时,血必净治疗组患者病死率显著低于对照组(P<0.05)。结论血必净结合西医治疗能够调节患者的免疫功能,改善SEPSIS病情和患者预后。
OBJECTIVE TO observe the effect of Xuebijing on degree of illness, blood levels of inflammatory mediators,incidence rate and mortality of sepsis syndrome (SEPSIS)so as to discuss its therapeutic mechanism on SEPSIS. METHODS A total of 60 patients with systemic inflammatory response syndrome in intensive care unit (ICU) were randomLy divided into treatment group and control group for an observation of clinical manifestation and prognosis . The plasma levels of procalcitonin (PCT) tumor necrosis factor-or (TNF-α) , interleukin-1β ( IL-1β ) , interleukin-6 (IL-6) of each patient were measured in order to determine the curative effect of Xuebijing. RESULTS The peasma level of PCT in treatment group was decreased significantly compared with control group. Xuebijing could down-regulate the levels of inflammatory mediators including TNFa, IL-1β and IL-6 ( P 〈 0.05 ). In addition, Xuebijing significantly reduced the mortality in treatment group compared with control group ( P 〈 0.05 ). CONCLUSION Xuebijing combined with western medicine could improve the immune function, illness state as well as prognosis of Sepsis patients.
出处
《海峡药学》
2007年第12期72-74,共3页
Strait Pharmaceutical Journal
关键词
脓毒症
血必净
免疫调节
Sepsis syndrome
Xuenbijing
Immunomodulative